INMUNE BIO INC. (INMB) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 9.15M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -20.20M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $9.15M | $-20.20M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $16.66M | (m) | $9.33M | $-43.29M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $20.66M | $50.00K | $9.91M | $-47.38M | (m) | 41318.00% | 19820.00% | (m) | (m) |
| 2025-09-30 | $25.68M | $50.00K | $8.35M | $-51.38M | (m) | 51366.00% | 16702.00% | (m) | (m) |
| 2025-06-30 | $30.86M | $50.00K | $7.09M | $-56.23M | (m) | 61726.00% | 14172.00% | (m) | (m) |
| 2025-03-31 | $32.11M | $50.00K | $7.90M | $-41.52M | $0.00 | 64224.00% | 15804.00% | (m) | Reported |
| 2024-12-31 | $33.17M | $14.00K | $7.61M | $-42.63M | $789.00K | 236900.00% | 54321.43% | -54.04× | Reported |
| 2024-09-30 | $31.82M | $42.00K | $7.73M | $-41.55M | $1.22M | 75761.90% | 18397.62% | -34.08× | Reported |
| 2024-06-30 | $27.74M | $85.00K | $7.90M | $-37.79M | $1.64M | 32632.94% | 9290.59% | -23.01× | Reported |
| 2024-03-31 | $24.83M | $131.00K | $7.41M | $-34.34M | $2.02M | 18956.49% | 5656.49% | -16.97× | Reported |
| 2023-12-31 | $20.27M | $155.00K | $7.37M | $-29.74M | $2.28M | 13079.35% | 4753.55% | -13.06× | Reported |
| 2023-09-30 | $17.68M | $224.00K | $7.28M | $-27.00M | (m) | 7891.07% | 3248.66% | (m) | (m) |
| 2023-06-30 | $16.85M | $279.00K | $7.33M | $-25.92M | (m) | 6039.43% | 2626.16% | (m) | (m) |
| 2023-03-31 | $16.89M | $249.00K | $7.35M | $-25.90M | (m) | 6783.53% | 2951.81% | (m) | (m) |
| 2022-12-31 | $17.07M | $374.00K | $7.15M | $-25.95M | (m) | 4563.37% | 1911.50% | (m) | (m) |
| 2022-09-30 | $20.73M | $440.00K | $6.88M | $-29.34M | (m) | 4710.23% | 1564.32% | (m) | (m) |
| 2022-06-30 | $22.09M | $356.00K | $6.55M | $-30.92M | (m) | 6203.93% | 1839.89% | (m) | (m) |
| 2022-03-31 | $22.36M | $340.00K | $5.43M | $-31.08M | (m) | 6576.76% | 1597.94% | (m) | (m) |
| 2021-12-31 | $20.54M | $181.00K | $4.80M | $-29.15M | (m) | 11349.72% | 2649.72% | (m) | (m) |
| 2021-09-30 | $15.33M | (m) | $3.98M | $-23.33M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $11.18M | (m) | $3.42M | $-19.13M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $7.62M | (m) | $3.33M | $-14.68M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $5.92M | $10.92K | $3.11M | $-12.23M | (m) | 54209.37% | 28508.65% | (m) | (m) |
| 2020-09-30 | $4.93M | (m) | $3.58M | $-11.35M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $3.73M | (m) | $3.51M | $-9.62M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $3.46M | (m) | $3.80M | $-7.94M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $3.28M | (m) | $4.10M | $-7.76M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $1.16M | (m) | $3.88M | $-7.30M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $1.11M | $0.00 | $3.88M | $-5.76M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $1.10M | $0.00 | $8.51M | $-11.50M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $1.11M | $0.00 | $10.00M | $-12.44M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $435.36K | $0.00 | $199.56K | $-981.48K | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |